1-3 of 3
Jarrod J. Sandow
Close
Sort by
Journal Articles

SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia

Lauren M. Brown, Soroor Hediyeh-zadeh, Teresa Sadras, Hannah Huckstep, Jarrod J. Sandow, Ray C. Bartolo, Hansen J. Kosasih, Nadia M. Davidson, Breon Schmidt, Stefan Bjelosevic, Ricky Johnstone, Andrew I. Webb, Seong L. Khaw, Alicia Oshlack, Melissa J. Davis, Paul G. Ekert
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2373–2387.
https://doi.org/10.1182/bloodadvances.2021006076
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

Emma Morrish, Anthony Copeland, Donia M. Moujalled, Jason A. Powell, Natasha Silke, Ann Lin, Kate E. Jarman, Jarrod J. Sandow, Gregor Ebert, Liana Mackiewicz, Jessica A. Beach, Elizabeth L. Christie, Alexander C. Lewis, Giovanna Pomilio, Karla C. Fischer, Laura MacPherson, David D. L. Bowtell, Andrew I. Webb, Marc Pellegrini, Mark A. Dawson, Stuart M. Pitson, Andrew H. Wei, John Silke, Gabriela Brumatti
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5062–5077.
https://doi.org/10.1182/bloodadvances.2020001576
Published: 2020
Includes: Supplemental data
Journal Articles

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression

Nicole L. Wittwer, Gabriela Brumatti, Ceilidh Marchant, Jarrod J. Sandow, Melanie K. Pudney, Mara Dottore, Richard J. D’Andrea, Angel F. Lopez, Paul G. Ekert, Hayley S. Ramshaw
Journal: Blood Advances
Blood Adv (2017) 1 (15): 1067–1079.
https://doi.org/10.1182/bloodadvances.2016002931
Published: 2017
Includes: Supplemental data